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Abstract
Purpose We examined whether diabetes and diabetes
treatment are associated with MD in a cohort study of
Danish women above age of 50 years.
Methods Study cohort consisted of 5,644 women (4,500
postmenopausal) who participated in the Danish Diet,
Cancer, and Health cohort (1993–1997) and subsequently
attended mammographic screening in Copenhagen
(1993–2001). We used MD assessed at the first screening
after the cohort entry, defined as mixed/dense or fatty.
Diabetes diagnoses and diabetes treatments (diet, insulin,
or oral antidiabetic agents) were self-reported at the time of
recruitment (1993–1997). The association between MD
and diabetes was analyzed by logistic regression adjusted
for potential confounders. Effect modification by meno-
pausal status and body mass index (BMI) was performed
by introducing an interaction term into the model and
tested by Wald test.
Results Of 5,644 women with mean age of 56 years, 137
(2.4%) had diabetes and 3,180 (56.3%) had mixed/dense
breasts. Having diabetes was significantly inversely
associated with having mixed/dense breasts, in both, the
crude model (odds ratio; 95% confidence interval: 0.33;
0.23–0.48), and after adjustment for adiposity and other
risk factors (0.61; 0.40–0.92). Similar inverse associations
were observed for 44 women who controlled diabetes by
diet only and did not receive any medication (0.56;
0.27–1.14), and 62 who took oral antidiabetic agents only
for diabetes (0.59; 0.32–1.09), while women taking insulin
had increased odds of mixed/dense breasts (2.08;
0.68–6.35). There was no effect modification of these
associations by menopausal status or BMI.
Conclusions Having diabetes controlled by diet or oral
antidiabetic agents is associated with a decrease in MD,
whereas taking insulin is associated with an increase in
MD.
Keywords Diabetes  Mammographic density  Breast
cancer  Insulin
Abbreviations
MD mammographic density
HT hormone therapy
CPR Danish personal identification number
DCH Diet, Cancer, and Health cohort
BI-RADS Breast Imaging Reporting and Data System
OR odds ratio
CI confidence interval
BMI body mass index
Introduction
Numerous studies have demonstrated an association
between type 2 diabetes and breast cancer [1–3]. A meta-
analysis found a 27% increase in breast cancer risk in
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women with type 2 diabetes, which attenuated to 13%
when adjusting for body mass index (BMI) [3]. Type 1
diabetes patients have no increased risk of breast cancer
[4]. Exact biological mechanisms behind possible associ-
ation between type 2 diabetes and breast cancer are
unknown, and the relationship is complicated since dia-
betes and breast cancer share many risk factors including
physical inactivity and obesity. Possible mechanisms
include direct effects of hyperinsulinemia or the insulin-
like growth factor (IGF) system on stimulating cell pro-
liferation, as well as indirect effects mediated through
altered levels of sex hormones [3]. Treatments which ele-
vate circulating insulin levels in people with diabetes may
increase cancer risk, and insulin analog glargine has been
associated with higher risk of breast cancer than human
insulin [5]. On the other hand, metformin, commonly
prescribed used oral antidiabetic regimen, which increases
insulin sensitivity and improves glycemic control, has been
found to reduce breast cancer risk [6]. However, a large
European study found no overall increase in breast cancer
for type two diabetic patients, irrespective of type of
treatment: sulfonylurea (hazard ratio (HR): 0.98), met-
formin (HR: 0.90), or insulin (HR: 1.07) [7].
One possible pathway from type 2 diabetes or diabetes
treatment to breast cancer could be via an intermediary
such as mammographic density (MD), one of the strongest
risk factors for breast cancer [8]. MD refers to the amount
of radiologically dense breast consisting of epithelial or
stromal tissue that appears light on a mammogram [9].
Women with more than 75% density in the breast have a
four to six times greater risk of breast cancer than women
with little density, or fatty breasts [10]. Known determi-
nants of MD include age at first birth, parity, age at
menopause, hormone therapy (HT), all of which are
estrogen-related, having a proliferative effect on fibrog-
landular tissue in the breast, increasing MD [10]. Use of
chemopreventive agents, such as tamoxifen, can reduce
MD [10]. Obesity, on the other hand, which increases the
risk of postmenopausal breast cancer, likely via insulin as a
mediator, decreases MD [10]. Only four studies examined
the association between self-reported diabetes and MD
[11–14], of which three reported slightly lower percent MD
(PMD) in diabetic as compared to non-diabetic women
[11–13], while a single study found statistically significant
inverse association between diabetes and MD in pre-
menopausal, but not in postmenopausal women [14]. No
study to date had examined whether effect of diabetes on
MD is differential by the type of treatment for diabetes.
Here we examined whether diabetes and diabetes
treatment are associated with MD in a prospective cohort
study of Danish women above age of 50 years.
Methods
Study population
The study population consists of 5,703 women above age
50 who participated in the Danish Diet, Cancer, and Health
(DCH) cohort between 1993 and 1997 and subsequently
attended the Copenhagen mammography screening pro-
gram between 1993 and 2001.
DCH cohort
Between 1993 and 1997, a total of 160,725 persons (72,729
women), 50–64 years of age, born in Denmark, living in
Copenhagen or Aarhus (the two largest cities in Denmark),
and free of cancer, were invited to participate in the DCH
cohort study. A total of 57,053 people, of whom 29,875
were women (37% of invited women and 7% of entire
Danish female population in this age group), accepted the
invitation and participated in the study, answering a com-
prehensive questionnaire on diet, health, education, occu-
pation, lifestyle, and reproductive factors. Height and
weight were measured at the time of recruitment by a
trained professional staff. Women were defined as pre-
menopausal if they reported no HT use and at least 1
instance of menstruation B12 months before the time of
recruitment, and postmenopausal otherwise. A detailed
description of the DCH cohort has been published previ-
ously [15].
Diabetes definition
Diabetes diagnosis (yes/no), age at diagnoses (years), and
form of treatment for diabetes (diet regulated, insulin, or
oral antidiabetic agents) were self-reported at the time of
recruitment (1993-1997) in the DCH cohort. We defined
diabetes as indicator (yes/no) of either having a diagnosis
of diabetes or being treated for diabetes (diet, insulin or
oral antidiabetic agents). Furthermore, we defined the three
indicators of treatment for diabetes: diabetes controlled by
diet only, insulin only, or oral antidiabetic agents only. We
could not distinguish between type 1 and type 2 diabetes.
Danish Copenhagen mammography register
The Copenhagen mammography screening program started
in 1991 [16] and targeted approximately 40,000 women
aged 50–69 years at the start of each biennial invitation
round. We used data from the first five screening rounds
between 1991 and 2001 [17]. Cases in which breast cancer
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was detected at the first screening were excluded from our
final analytic data set, as these women lacked MD data.
MD definition
One radiologist was in charge of the Copenhagen mam-
mography screening program between 1991 and 2001
which took place at a single Copenhagen hospital,
Rigshospitalet. All screens were taken by the radiographers
or X-ray nurses, and were evaluated independently by two
radiologists, who did not meet the attending women. A
two-view mammography, craniocaudal and oblique, was
performed at the initial screening. MD was dichotomized
into fatty breast, equivalent to Breast Imaging Reporting
and Data System (BI-RADS, Atlas, 2008) density code one
and part of code two, and mixed/dense breast, equivalent to
part of BI-RADS code two, and BI-RADS code three or
four. Women with a negative screening test and fatty
breasts were scheduled to have only an oblique view at
their next screening, whereas women with a negative
screening test and mixed/dense breasts were scheduled for
another two-view mammogram. MD was not coded for
positive screening mammograms. The dichotomous out-
come for MD has been successfully utilized in earlier
studies, showing the expected associations with breast
cancer risk [17] and validated against BI-RADS density
scores, with good agreement [18]. Using the personal
identification number (CPR) of the Danish Civil Registra-
tion System [19], we linked the Copenhagen mammogra-
phy register to the DCH cohort. We used MD assessed at
the first screening after the cohort baseline (1993–1997).
Statistical methods
We used logistic regression to investigate the association
between diabetes and the three possible diabetes treatments
(diet regulated/insulin/oral antidiabetic agents) and MD in
separate models, and in four steps: crude model (Model 1);
a model adjusted for age (Model 2); a Model 2 additionally
adjusted for BMI (kg/m2) and waist circumference (cm)
(Model 3), and Model 3 additionally adjusted for education
(B7 years/8–10 years/[ 10 years), alcohol use (yes/no),
alcohol intake (g/day), smoking (current/ever/never),
physical activity in leisure time (yes/no), number of chil-
dren, benign breast tumor (yes/no), and HT use (ever/
never) (Model 4). We did not have data on chemopre-
ventive agents in this cohort and did not include age at first
birth and menopausal status in the model, as large number
of women had missing data for these variables, 1,325 and
996, respectively. Analyses were stratified by menopausal
status, overweight (BMI C 25) and obesity (BMI C 30).
Effect modification of an association of MD with diabetes
by menopausal status, overweight (BMI C 25), and obesity
(BMI C 30) was analyzed by introducing an interaction
term into the model and tested by Wald test. Logistic
procedure in Stata 12.0 was used to conduct the analyses.
Results are presented as odds ratios (ORs) with 95% con-
fidence intervals (95% CI). We have run an additional
model with diabetes defined as diabetes with onset after
age 30 years, which could considered likely to be type two
diabetics (excluding likely type 1 diabetes patients who
typically are diagnosed before age 30 years).
Results
Of 5,703 women in the study, we excluded 59 with
missing data on one or more covariates, leaving 5,644
women for final analyses. Of these, 137 (2.4%) women
had reported having diabetes at cohort baseline, 44 did not
receive any medication and controlled diabetes by diet
only, 62 took oral antidiabetic agents only, and 20 took
insulin only, while 11 women answered that they used two
regimens for treating diabetes, and were thus not included
in the specific regimen analyses. The majority of women
(56.3%) had mixed/dense breasts at their mammogram,
which was taken at screening on average 1.1 years after
the cohort baseline (93% had their mammogram within
2 years after baseline).
Mean age at baseline was 56 years, and 4,500 (79.7%)
women were postmenopausal (Table 1). Mean BMI at
baseline was 25.9 kg/m2, half (51.1%) of the women were
overweight (BMI C 25 kg/m2), and 16.7% were obese
(BMI C 30 kg/m2). Women with mixed/dense breasts
were younger and had lower BMI than women with fatty
breasts (Table 1). Mean age at diabetes diagnoses was
52.8 years, 59.5 years for women regulating diabetes by
diet, 53.6 years for women taking oral antidiabetic agents,
and 41.2 years for women taking insulin (Table 2). A total
of 121 women received a diagnosis after age 30, which is
considered to be most likely type 2 diabetes (Table 2), and
in this group, age of onset of diabetes was 51.3 years for
those taking insulin. Diabetic women taking insulin had
lower BMI (24.0 kg/m2) than women regulating diabetes
by diet (31.0 kg/m2) or taking oral antidiabetic agents
(30.6 kg/m2). Of 16 who were diagnosed with diabetes
before age 30 and had likely type 1 diabetes, seven had
mixed/dense and five had fatty breasts (results not shown).
We found statistically significant inverse association
between having diabetes and MD in a crude model (OR;
95% CI: 0.33; 0.23–0.48), which attenuated after adjust-
ment for risk factors, especially adiposity, but remained
statistically significant (0.61; 0.40–0.92) (Table 3). Similar
inverse associations, although not statistically significant,
were observed for women with diabetes controlled by diet
only (0.56; 0.27–1.14), and for women taking oral
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Table 1 Diabetes prevalence and characteristics for 5,644 women from Diet, Cancer, and Health cohort, by mammographic density
Mammographic density
Total n = 5,644 Mixed/dense n = 3,180 Fatty n = 2,464
Diabetes
Diabetes, n (%) 137 (2.4) 42 (1.3) 95 (3.9)
Diabetes controlled by diet only, n (%) 44 (0.8) 13 (0.4) 31 (1.3)
Diabetes treatment by oral antidiabetic agents only, n (%) 62 (1.1) 16 (0.5) 46 (1.9)
Diabetes treatment by insulin only, n (%) 20 (0.3) 15 (0.5) 5 (0.2)
Cohort Participant Characteristics
Mean (SD) age (years) 56.3 (4.5) 55.4 (4.3) 57.3 (4.4)
Menopause, n (%) 4,500 (79.7) 2,444 (76.9) 2,056 (83.4)
Mean (SD) BMI (kg/m2) 25.9 (4.7) 24.6 (3.9) 27.6 (5.0)
Mean (SD) waist circumference (cm) 82.4 (11.8) 79.0 (10.1) 86.7 (12.4)
Overweight, n (%) 2,878 (51.0) 1,242 (39.1) 1,636 (66.4)
Obese (BMI[ 30 kg/m2), n (%) 946 (16.8) 298 (9.4) 648 (26.3)
Short education (B7 years), n (%) 2,023 (35.8) 988 (31.1) 1,035 (42.0)
Medium education (8–10 years), n (%) 2,757 (48.9) 1,601 (50.3) 1,156 (46.9)
Long education ([10 years), n (%) 864 (15.3) 591 (18.6) 273 (11.1)
Alcohol use, n (%) 5,454 (96.6) 3,082 (96.9) 2,372 (96.3)
Mean (SD) alcohol use in users (g/day) 13.8 (16.6) 14.8 (16.5) 12.6 (16.5)
Never smoked, n (%) 2,053 (36.5) 1,161 (36.6) 892 (36.4)
Previously smoked, n (%) 1,241 (22.1) 686 (21.6) 555 (22.6)
Current smoker, n (%) 2,330 (41.4) 1,324 (41.7) 1,006 (40.0)
Physically active, n (%) 2,696 (47.8) 1,571 (49.4) 1,125 (45.7)
Nulliparous, n (%) 835 (14.8) 559 (17.6) 276 (11.2)
Mean (SD) number of childrena 2.2 (0.9) 2.0 (0.8) 2.3 (1.0)
Mean (SD) age at first birth (years) 22.6 (4.2) 22.8 (4.2) 22.3 (4.1)
Had benign breast tumor, n (%) 740 (13.1) 528 (16.6) 212 (8.6)
Ever used HT 2,705 (47.9) 1,633 (51.3) 1,072 (43.5)
Mean (SD) HT duration in ever users (years) 6.0 (6.0) 5.9 (5.9) 6.1 (6.1)
SD standard deviation, BMI body mass index, HT hormone therapy
a in parous women
Table 2 Adiposity and age at diagnoses distribution by diabetes treatment in 5,644 women from Diet, Cancer, and Health cohort
Total Total n = 5,644 All diabetes n = 137 Diet n = 44 Oral antidiabetic agents n = 62 Insulin n = 20
Mean (SD) BMI (kg/m2) 25.9 (4.7) 30.1 (5.8) 31.0 (6.4) 30.6 (4.5) 24.0 (5.2)
Overweight, n (%) 2,878 (51.0) 110 (80.3) 38 (86.4) 54 (87.1) 6 (30.0)
Obese, n (%) 946 (16.8) 67 (48.9) 20 (45.4) 34 (54.8) 3 (15.0)
Mean (SD) age at diagnosesa - 52.8 (14.5) 59.5 (14.1) 53.6 (13.1) 41.2 (19.5)
Diabetes above age 30 Total n = 5,640 All diabetes n = 121 Diet n = 36 Oral antidiabetic agents n = 56 Insulin n = 12
Mean (SD) BMI (kg/m2) 25.9 (4.7) 30.7 (5.5) 31.9 (6.4) 30.9 (4.5) 26.1 (5.8)
Overweight, n (%) 2,876 (51.0) 103 (85.1) 33 (91.7) 50 (89.3) 6 (50.0)
Obese, n (%) 946 (16.8) 64 (52.9) 18 (50.0) 32 (57.1) 3 (25.0)
Mean (SD) age at diagnosesa - 56.6 (7.8) 59.6 (6.4) 57.0 (6.0) 51.3 (12.1)
Overweight = BMI[ 25 kg/m2; Obese = BMI[ 30 kg/m2
a for 133 women who have reported age at diabetes diagnoses
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antidiabetic agents only (0.59; 0.32–1.09) in the fully
adjusted model. For women with diabetes taking insulin,
we found a positive association with MD in all models,
although statistically non-significant, due to small numbers
(2.08; 0.68–6.35). Associations between diabetes and MD
were slightly enhanced when limiting analyses to women
with diabetes onset after age 30 (0.55; 0.35–0.87), mostly
for women controlling diabetes by diet only (0.36;
0.15–0.86), while they remained unchanged for women
taking oral antidiabetic agents (0.59; 0.31–1.13), and were
slightly reduced for women taking insulin (2.01;
0.55–7.44), but there was no statically significant differ-
ence with estimates for all diabetes, regardless of age at
onset (Table 3).
In stratified analyses, we found that there was no dif-
ference in association between diabetes and MD by
menopausal status, or BMI (Table 4).
Discussion
In this study, we present novel results of the differential
association between diabetes and MD by diabetes treat-
ment. Inverse associations between diabetes and MD were
observed for women who controlled diabetes with diet or
oral antidiabetic agents, while women taking insulin
showed a positive association with having mixed/dense
breasts, though statistically non-significant.
Our results generally agree with four studies on diabetes
prevalence and MD, although differences in study design,
study populations, and MD assessment preclude direct
comparisons. The study by Tehranifar et al. [11] is a cross-
sectional study from the New York Multiethnic Breast
Cancer Project based on 124 pre- and 67 postmenopausal
women with data on PMD, of whom 16 reported having
type 2 diabetes. Mammograms were collected on the same
date or 14 days after the interview. Diabetic women had
slightly lower PMD than non-diabetic women, but the
difference was not statistically significant [11]. Sellers
et al. [12] utilized data from the Minnesota Breast Cancer
Family Study Cohort to examine the association of PMD
assessed shortly after interview in 2,530 women above age
40, where 161 reported diabetes, and found no statistically
significant association, although mean PMD was slightly
lower in diabetic women than in women without diabetes.
Sanderson et al. [13] has in 476 black American women
recruited at Meharry Medical College detected a lower
percent breast density in 373 women with diabetes than in
those without diabetes, but only in premenopausal women
and without statistical significance, and no difference in
postmenopausal women. Finally, Roubidoux et al. inves-
tigated the association between self-reported diabetes
(n = 152) with MD available as BIRADS density scores
among 144 pre- and 311 postmenopausal Southwestern
Native American women, and found that diabetes was
statistically significantly associated with lower BIRADS
Table 3 Association between diabetes and MD among 5,644 women in Diet, Cancer, and Health cohort who participated in mammographic
screening in Copenhagen
MD Model 1 Crude Model 2
Age-adjusted
Model 3 Model
2 ? adipositya
Model 4 Fully
adjustedb
Mixed/
dense
Fatty
n n n OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
No diabetes 5,507 3,138 2,369 1.00 1.00 1.00 1.00
All diabetes 137 42 95 0.33 (0.23–0.48) 0.34 (0.24–0.50) 0.62 (0.42–0.93) 0.61 (0.40–0.92)
Diabetes/diet only 44 13 31 0.32 (0.17–0.62) 0.33 (0.17–0.64) 0.62 (0.30–1.27) 0.56 (0.27–1.14)
Diabetes/oral antidiabetic agents only 62 16 46 0.27 (0.15–0.47) 0.27 (0.15–0.48) 0.56 (0.30–1.02) 0.59 (0.32–1.09)
Diabetes/insulin only 20 15 5 2.33 (0.85–6.43) 2.70 (0.96–7.54) 2.32 (0.78–6.90) 2.08 (0.68–6.36)
Diabetes above age 30c
No diabetes 5,519 3,146 2,373 1.00 1.00 1.00 1.00
All diabetes 121 32 89 0.27 (0.18–0.41) 0.28 (0.18–0.42) 0.56 (0.36–0.86) 0.55 (0.35–0.87)
Diabetes/diet only 36 7 29 0.18 (0.08–0.42) 0.19 (0.08–0.45) 0.38 (0.15–0.92) 0.36 (0.15–0.86)
Diabetes/oral antidiabetic agents only 56 14 42 0.25 (0.14–0.47) 0.25 (0.14–0.47) 0.57 (0.30–1.08) 0.59 (0.31–1.13)
Diabetes/insulin only 12 8 4 1.55 (0.47–5.16) 1.85 (0.55–6.23) 2.12 (0.58–7.72) 2.01 (0.55–7.44)
OR odds ratio, CI confidence interval
a adjusted for age, body mass index (BMI) and waist circumference
b adjusted for age, BMI, waist circumference, menopausal status, education (\8 years, 8–10 years,[10 years), alcohol use (yes/no), alcohol
intake (g/day), smoking (current/previous/never), number of children, benign breast tumor (yes/no), and HT use (ever/never)
c for 133 women who reported age at diabetes diagnoses
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density in premenopausal women only, but found no
association in postmenopausal women [14]. We found
inverse, statistically significant associations between hav-
ing diabetes and MD, in both pre- and postmenopausal
women, although with slightly stronger associations in
premenopausal women, in agreement with Sanderson et al.
[13] and Roubidoux et al. [14]. Overall, evidence seems
consistent that women with diabetes have less dense
breasts than women without diabetes, in studies that control
for BMI and adiposity. Diabetes reduces breast density,
which is one of the strongest risk factors for breast cancer
[10], but it, independently of breast density, increases the
risk of breast cancer. The mechanisms by which type 2
diabetes increases the risk of breast cancer are not known,
but several pathways are possible. Type 2 diabetes causes
hyperglycemia, hyperinsulinemia, and increased inflam-
mation, all of which may increase risk of breast cancer
[1–3]. In addition, type 2 diabetes and breast cancer share
many risk factors, including age, physical inactivity,
overweight, and obesity, which may separately or together,
increase risk of breast cancer in postmenopausal women
with diabetes [1–3]. Overweight and obesity, for example,
as type 2 diabetes, are associated with decrease in breast
density [10], but increase in breast cancer risk in post-
menopausal women.
We present the novel results that the association
between diabetes and MD is differential with respect to
type of treatment for diabetes. We found that women who
take insulin have likely increased, whereas women taking
oral antidiabetic agents or not taking any mediation have
strongly decreased breast density, compared to women
without diabetes. The exact biological mechanism behind
these novel findings are not known, but some plausibility
for the findings comes from existing evidence on associa-
tions between different diabetes treatment and breast can-
cer. Earlier studies have shown that insulin, a debated risk
factor for breast cancer [4, 20], can stimulate cell prolif-
eration in human breast cancer cell lines [21] and also in
normal breast tissue [22, 23]. Thus, it is plausible that
insulin can increase the amount of fibroglandular tissue in
the breast, hence increasing MD [3, 20]. Several small
studies examined association between fasting circulating
insulin plasma levels and MD and found none, but have
typically included healthy women without diabetes
[24, 25]. Metformin, a biguanide, is the most commonly
used oral medication for first-line treatment of diabetes.
Table 4 Effect modification of the associationa between diabetes and MD by menopausal status and BMI, among 5,644 women in Diet, Cancer,
and Health cohort who participated in mammographic screening in Copenhagen
Mixed/dense n Fatty n OR (95% CI) Mixed/dense n Fatty n OR (95% CI) p value
Premenopausal (n = 1,144) Postmenopausal (n = 4,500)
No diabetes 728 390 1.00 2,410 1,979 1.00
All diabetes 8 18 0.51 (0.20–1.26) 34 77 0.64 (0.41–1.01) 0.57
Diabetes/diet 5 6 0.54 (0.14–2.13) 8 25 0.54 (0.23–1.27) 0.98
Diabetes/oral antidiabetic agents 3 9 0.52 (0.13–2.13) 13 37 0.60 (0.30–1.20) 0.80
Diabetes/insulin 2 1 2.40 (0.21–27.3) 13 4 2.14 (0.61–7.51) 0.92
Normal weight, BMI\ 25 (n = 2,766) Overweight, BMI C 25 (n = 2,878)
No diabetes 1,921 818 1.00 1,217 1,551 1.00
All diabetes 17 10 0.91 (0.39–2.11) 25 85 0.52 (0.32–0.84) 0.84
Diabetes/diet 5 1 1.81 (0.19–17.0) 8 30 0.43 (0.19–0.98) 0.24
Diabetes/oral antidiabetic agents 1 7 0.16 (0.02–1.39) 15 39 0.71 (0.37–1.35) 0.18
Diabetes/insulin 12 2 2.35 (0.48–11.6) 3 3 1.67 (0.31–9.11) 0.74
Not obese, BMI\ 30 (n = 4,698) Obese, BMI C 30 (n = 946)
No diabetes 2,850 1,778 1.00 288 591 1.00
All diabetes 32 38 0.69 (0.41–1.15) 10 57 0.43 (0.21–0.89) 0.44
Diabetes/diet 10 14 0.59 (0.24–1.40) 3 10 0.46 (0.13–1.67) 0.94
Diabetes/oral antidiabetic agents 9 19 0.51 (0.22–1.18) 7 27 0.61 (0.25–1.47) 0.63
Diabetes/insulin 15 2 3.72 (0.81–17.1) 0 3 NA
OR odds ratio, CI confidence interval
a adjusted for age, body mass index (BMI) waist circumference, menopausal status, education (\8 years, 8–10 years,[10 years), alcohol use
(yes/no), alcohol intake (g/day), smoking (current/previous/never), number of children, age at first birth, benign breast tumor (yes/no), and HT
use (ever/never)
18 Cancer Causes Control (2017) 28:13–21
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Metformin has multiple biological effects which can con-
tribute to anticancer effects, including either direct
antiproliferative effects or through indirect mechanisms,
such as lowering of circulating insulin levels and improv-
ing glycemic control in diabetes patients [26]. In line with
these physiological effects, metformin was found to lower
postmenopausal breast cancer risk in some [6, 27] but not
all studies [7]. Furthermore, metformin can reduce circu-
lating androgen and estrogen levels [28]. Thus, it is plau-
sible that metformin, by reducing levels of endogenous
estrogen and cell proliferating insulin, can reduce MD.
However, we found similar effect of decreased MD on both
groups of women taking oral antidiabetic agents and reg-
ulating diabetes by diet only, precluding the conclusion
that metformin alone can decrease MD, but rather sug-
gesting that some other factor or characteristic common to
both groups of diabetic women who did not take insulin
contributes to lower MD.
This study benefited from having access to a large
cohort of women with self-reported diabetes at recruitment
in 1993–1999 as well as subsequent and independent col-
lection of data on MD at breast cancer screening, facili-
tating the prospective design and limiting the possibility of
recall or information bias. We had data and were able to
adjust for all major diabetes and breast cancer risk factors
and determinants of MD. Unlike any study before [11–14],
we had objectively measured data on height and weight
(BMI) and waist circumference, and were thus able to
extensively adjust for adiposity, which is an important risk
factor for diabetes and very important determinant for MD,
as shown in Table 2. A major strength of this study is also
the availability of information on diabetes treatment regi-
ments, enabling us to examine the effect of diabetes regi-
ments on MD for the first time. Furthermore, this is one of
the largest studies to date on diabetes and MD, and perhaps
the first study with enough power to detect statistically
significant inverse associations between diabetes and MD,
in contrast to earlier, smaller studies of typically few
hundred patients [11–14]. Still, based on 137 diabetes
cases, we still had limited power in the effect modification
analyses. The main limitation is the possible misclassifi-
cation of diabetes treatment, which is self-reported, as well
as the small number of diabetes cases, limiting the power in
analyses of diabetes treatment. Furthermore, we could not
distinguish between type one and type 2 diabetes, but we
found consistent results in a subset of women who most
likely had type 2 diabetes (those with onset of diabetes
above age 30 years). We also lacked the data on the
specific type of insulin or oral antidiabetic agent regiments,
although most of the patients in Denmark are prescribed
metformin as oral diabetic agent. Recent report based on
national data in Denmark between 2005 and 2012 showed
that 81% of type 2 diabetes patients received metformin as
their first antidiabetic medication, 13% started with sul-
fonylurea, and 6% with insulin [29]. We excluded women
with positive outcome at the initial breast cancer screening,
as they were not assigned MD, but instead referred to
additional testing, by which we have likely excluded
women with high MD, which is associated with breast
cancer and low screening sensitivity. Another weakness is
that DCH cohort participants are likely healthier than the
general Danish population, implying some healthy worker
effect, as it was shown that they are better educated and
had higher income than non-participants [15]. Another
limitation is that diabetes is self-reported, and likely
underreported. However, self-reported diabetes prevalence
in this cohort of 2.4% corresponds well to diabetes
prevalence data for entire Denmark, based on Danish
Diabetes register, which ranged from 1995 (first data in
register) to 1997, in women, from 1.9 to 2.4%, [30].
In conclusion, we found that diabetic women had lower
MD than women without diabetes, but that the association
was differential by type of diabetes regimen. Having dia-
betes controlled by diet or oral antidiabetic agents seems to
decrease, whereas taking insulin may increase MD. This
information is important for women taking insulin and
clinicians working with diabetes and breast cancer
screening. Women with type 2 diabetes are at increased
risk of breast cancer and have poorer prognosis of breast
cancer [31], and as high risk group may have an added
benefit from attending breast cancer screening and detect-
ing cancer early. However, women with diabetes partici-
pate less in breast cancer screening than women from
general population, and seem to miss out on the screening
benefits [31]. Furthermore, increase in MD in women
taking insulin may reduce the sensitivity of the screening in
this group of diabetic women, as breast cancer screening
performance decreases with increasing breast density [32].
Thus, diabetic women may benefit from better information
on benefits of breast cancer screening, and the effect of
their diabetes treatment regimen on breast density and
related cancer screening performance, all of which may
reduce breast cancer burden in this group of women. More
research is needed to reproduce findings of this novel
study.
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